Your browser doesn't support javascript.
loading
Minimal Residual Disease-Guided Intermittent Dosing in Patients With Cancer: Successful Treatment of Chemoresistant Anaplastic Large Cell Lymphoma Using Intermittent Lorlatinib Dosing.
Pokorna, Petra; Lakka Klement, Giannoula; Vasikova, Alzbeta; Kanderova, Veronika; Jezova, Marta; Noskova, Kristyna; Mudry, Peter; Kyr, Michal; Merta, Tomas; Bajciova, Viera; Krenova, Zdenka; Palova, Hana; Valik, Dalibor; Zdrazilova Dubska, Lenka; Slaby, Ondrej; Sterba, Jaroslav.
Afiliación
  • Pokorna P; Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
  • Lakka Klement G; Department of Pediatric Oncology, University Hospital Brno, and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
  • Vasikova A; CSTS Health Care, Toronto, ON, Canada.
  • Kanderova V; Department of Internal Medicine-Hematology and Oncology, University Hospital Brno, and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
  • Jezova M; CLIP, Department of Pediatric Hematology/Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic.
  • Noskova K; Department of Pathology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
  • Mudry P; Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
  • Kyr M; Clinical Pharmacy Section of Hospital Pharmacy, University Hospital Brno, Brno, Czech Republic.
  • Merta T; Department of Pediatric Oncology, University Hospital Brno, and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
  • Bajciova V; Department of Pediatric Oncology, University Hospital Brno, and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
  • Krenova Z; Department of Pediatric Oncology, University Hospital Brno, and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
  • Palova H; Department of Pediatric Oncology, University Hospital Brno, and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
  • Valik D; Department of Pediatric Oncology, University Hospital Brno, and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
  • Zdrazilova Dubska L; Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
  • Slaby O; Department of Laboratory Methods, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
  • Sterba J; Department of Clinical Microbiology and Immunology, University Hospital Brno, and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
JCO Precis Oncol ; 6: e2100525, 2022 06.
Article en En | MEDLINE | ID: mdl-35700412
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Linfoma Anaplásico de Células Grandes Límite: Humans Idioma: En Revista: JCO Precis Oncol Año: 2022 Tipo del documento: Article País de afiliación: República Checa
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Linfoma Anaplásico de Células Grandes Límite: Humans Idioma: En Revista: JCO Precis Oncol Año: 2022 Tipo del documento: Article País de afiliación: República Checa